Compare Amphastar Pharmaceuticals Inc (AMPH) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) trades at $91.50 with minimal daily movement, reflecting its stable Treasury bill portfolio. The ETF maintains consistent $0.27 quarterly dividends and shows bearish technical signals despite neutral oscillators. Recent market focus compares short-term Treasury ETFs like BIL against money market alternatives as investors seek yield amid Federal Reserve policy uncertainty.

BIL offers low-risk cash parking with Treasury bill exposure, but faces pressure from potential Fed rate hikes that could impact short-term yields. The ETF's stability appeals to risk-averse investors, though higher-yielding alternatives may emerge if rates rise further. Current technical weakness suggests cautious near-term positioning despite fundamental safety.